<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387932</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-P3-11-01</org_study_id>
    <nct_id>NCT01387932</nct_id>
  </id_info>
  <brief_title>HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer</brief_title>
  <acronym>HiQuality</acronym>
  <official_title>Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate overall survival in patients treated with
      HepaSphere/QuadraSphere compared to conventional transarterial chemoembolization with
      particle PVA.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates (ORR)</measure>
    <time_frame>Approx 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in the treated area</measure>
    <time_frame>Approx 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Approx 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization</measure>
    <time_frame>Approx 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HepaSphere/QuadraSphere TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HepaSphere/QuadraSphere TACE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HepaSphere/QuadraSphere Microspheres</intervention_name>
    <description>HepaSphere/QuadraSphere Microspheres loaded with doxorubicin</description>
    <arm_group_label>HepaSphere/QuadraSphere TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVA, lipiodol, doxorubicin</intervention_name>
    <description>Conventional TACE procedure using PVA, lipiodol and doxorubicin</description>
    <arm_group_label>Conventional TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet all of the following inclusion criteria in order to be entered into the
        study:

          1. Age 18 or older

          2. Patient has signed informed consent

          3. Patient must have a diagnosis of hepatocellular cancer confirmed by at least one of
             the following:

        i. Histological confirmation ii. Magnetic resonance imaging (MRI) result with early
        enhancement and delayed enhancement washout of at least one solid liver lesion &gt; 1 cm.
        Patient must also have evidence of cirrhosis or have chronic hepatitis B.

        iii. Contrast enhanced computed tomography (CT) with early enhancement and delayed
        enhancement washout of at least one solid liver lesion &gt; 1cm. Patient must also have
        evidence of cirrhosis or have chronic hepatitis B.

        d. Patient must not be suitable for treatment by resection or percutaneous ablation at time
        of study entry.

        Patients not suitable for ablation due to lesion location may be enrolled

        e. Patient MUST meet at least ONE of the following criteria:

        i. Stage Child-Pugh B 7 ii. Recurrent HCC iii.Performance status ECOG 1

        f. Patient has a life expectancy of at least 6 months

        g. Absence of occlusive thrombus to the main portal trunk

        Exclusion Criteria:

        If patients meet any of the following criteria they may not be entered into the study:

          1. Current or previous treatment with chemo- or radiation therapy or sorafenib

          2. Previous treatment with any form of transarterial embolization for HCC

          3. Patients with current or history of any other cancer except non-melanomatous skin
             cancer

          4. Female patients who are pregnant, breastfeeding, or premenopausal and not using an
             effective method of contraceptive

          5. Performance status ECOG &gt; 2

          6. Child-Pugh scores &gt;7

          7. Active gastrointestinal bleeding

          8. Evidence of uncorrectable bleeding diathesis

          9. Extra-hepatic spread of the HCC

         10. Total Bilirubin &gt; 3 mg/dL

         11. &gt;50% tumor involvement of the liver

         12. Infiltrative or diffuse HCC

         13. Encephalopathy not adequately controlled medically

         14. Presence of ascites not controlled medically

         15. Presence of medically relevant localized or systemic infection, other than hepatitis
             B, C, D, E or G

         16. Any contraindication for MRI (eg. metallic implants)

         17. Allergy to contrast media that cannot be managed with prophylaxis

         18. Allergy to iodized oil

         19. Any contraindication to arteriography

         20. Any contraindication for doxorubicin administration, including the following:

        i. White Blood Cell count (WBC) &lt;3000 cells/mm₃

        ii. Absolute Neutrophil &lt;1500 cells/mm₃

        iii. Cardiac ejection fraction &lt;50%

        iv. Other condition deemed exclusionary by physician

        u. Any contraindication for hepatic embolization, including the following:

        i. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior
        to chemoembolization

        ii. Hepatofugal blood flow

        iii. Serum creatinine &gt; 2mg/dL

        iv. Uncorrectable impaired clotting

          1. Platelet &lt;50,000/mm₃

          2. International Normalized Ratio (INR) &gt; 1.4

          3. Activated Prothrombin Time (aPTT) less than 21 or greater than 40

             v. AST &gt; 5X upper limit of normal for lab

             vi. ALT &gt; 5X upper limit of normal for lab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Soulen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Lencioni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Independent Radiology Panel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Llovet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Data Safety Monitoring Board</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuscon Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Arkansas Veterans Healthcare</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Veterans Institute for Research</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Healthcare</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Medical Center (Medical University of South Carolina)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health and Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals K.U. Leuven (Dept of Hematology)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Paul Brousse</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evgenidion University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Croce e Carle Hospital</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Egypt</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>TACE</keyword>
  <keyword>HepaSphere Microspheres</keyword>
  <keyword>QuadraSphere Microspheres</keyword>
  <keyword>Doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

